Cerecin Is A Healthcare Company Based In Denvercoloradospecializing In Innovative Treatments For Neurological Diseaseswith Over 20 Years Of Experiencethe Company Focuses On The Metabolic Basis Of Brain Disordersaiming To Improve Patient Outcomes Through Evidence Based Therapeuticscerecin S Team Is Dedicated To Advancing Brain Health By Leveraging Expertise In Neuroscience And Metabolism To Create Therapies That Target The Underlying Mechanisms Of Diseases The Company Develops Novel Therapeutics Designed To Treat A Variety Of Neurological Conditionsincluding Migraine And Infantile Spasmscerecin S Approach Emphasizes Metabolic Interventionsdistinguishing It Within The Neuroscience Fieldtheir Primary Customers Include Patients With Neurological Diseases And Healthcare Providers Involved In Their Treatmentoffering Innovative Options That Address The Root Causes Of Neurological Dysfunction Cerecin Has An Estimated Enterprise Valuation Between $160 Million And $240 Million As Of August 2022 And Has Secured Significant Funding To Support Its Research And Development Effortsthe Company Is Committed To Pioneering Treatments That Enhance Brain Health And Improve The Lives Of Those Affected By Neurological Disorders
